Postoperative nausea and vomiting after artificial joint replacement surgery: comparison between remimazolam and

Kazuma Yunoki1, Hiroyuki Mima2

  • 1The Department of Anesthesiology and Critical Care, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 6500047, Japan. yunokik@kcho.jp.

Journal of Anesthesia
|July 15, 2023
PubMed
Abstract

Insights

Remimazolam and sevoflurane anesthesia show no significant difference in causing postoperative nausea and vomiting (PONV) after joint replacement surgery. This study compared the incidence of PONV between these two anesthetic agents.

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Postoperative nausea and vomiting (PONV) is a common complication following anesthesia.
  • Remimazolam is a novel ultrashort-acting benzodiazepine with potential anesthetic applications.
  • Sevoflurane is a widely used volatile anesthetic agent.

Purpose of the Study:

  • To compare the incidence of postoperative nausea and vomiting (PONV) between remimazolam and sevoflurane.
  • To evaluate anesthetic efficacy for artificial joint replacement surgery.

Main Methods:

  • Retrospective analysis of electronic medical records from 2020-2022.
  • Propensity score matching to control for confounding factors.
  • Comparison of PONV incidence in sevoflurane versus remimazolam anesthesia groups.

Main Results:

  • Initial analysis of 292 patients showed no significant difference in PONV incidence (p=0.461).
  • After propensity score matching (51 patients per group), no significant difference in PONV incidence was observed (p=0.243).
  • Age and ASA-PS differed significantly before matching but were balanced post-matching.

Conclusions:

  • Remimazolam and sevoflurane exhibit comparable safety profiles regarding PONV in patients undergoing artificial joint replacement.
  • Neither anesthetic agent demonstrated a significant advantage in preventing PONV in this patient population.

Related Concept Videos

General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
245
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
323
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
346
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
204
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
249
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
158